Table IV.
Comparison between patients with clinically significant bleeding and patients with non-clinically significant bleeding.
| Variable | Clinically significant (n = 105) | Not clinically significant (n = 51) | p-value |
|---|---|---|---|
| Age | 67 (±17) | 62 (±22) | NS |
| Gender | 48% female | 31% female | NS |
| Hb | 82 (±13.2) | 120 (±21.6) | 0.0001 |
| Hematocrit | 0.25 (±0.037) | 0.35 (±0.058) | 0.0001 |
| Platelets | 255 (±148) | 227 (±104) | NS |
| Creatinine | 106 (±125) | 94 (±60) | NS |
| PT | 15.3 (±2.2) | 13.8 (±2) | NS |
| INR | 2.5 (1.4) | 1.4 (0.4) | NS |
| Duodenal ulcer | 25 (24%) | 7 (14%) | NS |
| Gastric ulcer | 20 (19%) | 3 (6%) | 0.031 |
| Mallory–Weiss tear | 8 (8%) | 11 (22 %) | NS |
| Esophagitis | 6 (6%) | 9 (18%) | NS |
| Unexplained bleeding | 2 (2%) | 8 (16%) | NS |
| Vascular ectasia | 2 (2%) | 6 (12%) | NS |
| Gastric and duodenal ulcer | 7 (7%) | 0 (0) | NS |
| Mucosal erosive disease | 4 (4%) | 3 (6%) | NS |
| Esophagal varices | 6 (6%) | 0 (0) | NS |
| Ulcer on anastomosis | 5 (5%) | 0 (0) | NS |
| Gastric cancer | 4 (4%) | 0 (0) | NS |
| GIST | 4 (4%) | 0 (0) | NS |
| Esophageal ulcer | 1 (1%) | 3 (6%) | NS |
| NSAIDs | 28 (26.7%) | 3 (5.9%) | 0.0023 |
| LDA | 45 (42.9%) | 17 (33.3%) | NS |
| Warfarin | 14 (13.3%) | 9 (17.6%) | NS |
| SSRI drugs | 17 (16.2%) | 8 (15.7%) | NS |
| Anti-platelet drugs | 4 (3.8%) | 7 (13.7%) | 0.0404 |
| Bisphosphonates | 6 (5.7%) | 1 (2%) | NS |
| NSAIDs + LDA | 13 (12.4%) | 0 (0%) | 0.0053 |
| LDA + SSRIs | 9 (8.6%) | 3 (5.9%) | NS |
| LDA + warfarin | 4 (3.8%) | 2 (3.9%) | NS |
| NSAIDs + SSRIs | 3 (2.9%) | 2 (3.9%) | NS |
Abbreviations: GIST = gastrointestinal stroma tumor; Hb = hemoglobin; INR = International Normalized Ratio; LDA = low-dose aspirin; NSAIDs = non-steroidal anti-inflammatory drugs; PT = prothrombin time; SD = standard deviation; SSRIs = selective serotonin receptor antagonists.
Data presented as mean ± SD or as count and percentage.